

CaMKK β siRNA (h): sc-38955

BACKGROUND

The Ca²⁺/calmodulin-dependent protein kinases (CaM kinases) are a structurally related subfamily of serine/threonine kinases that includes CaMKI, CaMKII and CaMKIV. CaMKI and CaMKIV are stimulated by Ca²⁺ and CaM, but phosphorylation by a CaMK is also required for full activation. CaMKK α and CaMKK β function to activate CaMKI through the specific phosphorylation of the regulatory threonine residue at position 177. CaMKK β is also capable of phosphorylating CaMKIV on threonine residue 200.

CHROMOSOMAL LOCATION

Genetic locus: CAMKK2 (human) mapping to 12q24.31.

PRODUCT

CaMKK β siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see CaMKK β shRNA Plasmid (h): sc-38955-SH and CaMKK β shRNA (h) Lentiviral Particles: sc-38955-V as alternate gene silencing products.

For independent verification of CaMKK β (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-38955A, sc-38955B and sc-38955C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

CaMKK β siRNA (h) is recommended for the inhibition of CaMKK β expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

GENE EXPRESSION MONITORING

CaMKK β (C-11): sc-271674 is recommended as a control antibody for monitoring of CaMKK β gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor CaMKK β gene expression knockdown using RT-PCR Primer: CaMKK β (h)-PR: sc-38955-PR (20 μ l, 464 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

SELECT PRODUCT CITATIONS

1. Zhang, J., et al. 2008. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. *J. Biol. Chem.* 283: 27452-27461.
2. Hattori, Y., et al. 2009. Cilostazol inhibits cytokine-induced nuclear factor- κ B activation via AMP-activated protein kinase activation in vascular endothelial cells. *Cardiovasc. Res.* 81: 133-139.
3. Chung, B.H., et al. 2012. Syringaresinol causes vasorelaxation by elevating nitric oxide production through the phosphorylation and dimerization of endothelial nitric oxide synthase. *Exp. Mol. Med.* 44: 191-201.
4. Zhang, L., et al. 2013. Pterostilbene, a natural small-molecular compound, promotes cytoprotective macroautophagy in vascular endothelial cells. *J. Nutr. Biochem.* 24: 903-911.
5. Dong, G.Z., et al. 2014. AMPK activation by isorhamnetin protects hepatocytes against oxidative stress and mitochondrial dysfunction. *Eur. J. Pharmacol.* 740: 634-640.
6. Deshmukh, R.R. and Dou, Q.P. 2015. Proteasome inhibitors induce AMPK activation via CaMKK β in human breast cancer cells. *Breast Cancer Res. Treat.* 153: 79-88.
7. Liu, D.M., et al. 2016. CAMKK2, regulated by promoter methylation, is a prognostic marker in diffuse gliomas. *CNS Neurosci. Ther.* 22: 518-524.
8. Choi, Y.K., et al. 2018. Heme oxygenase metabolites improve astrocytic mitochondrial function via a Ca²⁺-dependent HIF-1 α /ERR α circuit. *PLoS ONE* 13: e0202039.
9. Sun, P., et al. 2019. Inhibition of calcium/calmodulin-dependent protein kinase kinase (CaMKK) exacerbates impairment of endothelial cell and blood-brain barrier after stroke. *Eur. J. Neurosci.* 49: 27-39.
10. Woo, S.M., et al. 2019. Hispidulin enhances TRAIL-mediated apoptosis via CaMKK β /AMPK/USP51 axis-mediated Bim stabilization. *Cancers* 11: 1960.
11. Wei, X., et al. 2020. Activation of TRPV1 channel antagonizes diabetic nephropathy through inhibiting endoplasmic reticulum-mitochondria contact in podocytes. *Metab. Clin. Exp.* 105: 154182.

RESEARCH USE

For research use only, not for use in diagnostic procedures.